MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis.

MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. Oncotarget (2015) 0.89

Identification of a blood-borne miRNA signature of synovial sarcoma. Mol Cancer (2015) 0.86

Dysregulation of non-coding RNAs in gastric cancer. World J Gastroenterol (2015) 0.84

Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis. Oncotarget (2017) 0.77

NF-κB Signaling in Gastric Cancer. Toxins (Basel) (2017) 0.75

The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity. Sci Rep (2017) 0.75

Prognostic value of microRNAs in gastric cancer: a meta-analysis. Oncotarget (2017) 0.75

MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

The functions of animal microRNAs. Nature (2004) 64.85

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell (2003) 11.07

Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature (1990) 9.31

Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67

Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell (2006) 7.32

Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88

The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature (2003) 6.11

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00

Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell (1996) 5.91

International variation. Oncogene (2004) 4.64

NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61

Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42

The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal (2010) 3.20

NF-kappaB as a therapeutic target in cancer. Trends Mol Med (2002) 3.08

Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem (2006) 2.32

Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23

CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ (2010) 2.14

The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09

Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00

Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. EMBO J (2007) 1.95

Treatment of gastric cancer. World J Gastroenterol (2014) 1.93

Expanding role of ubiquitination in NF-κB signaling. Cell Res (2010) 1.89

Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J (2008) 1.87

NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem (2008) 1.74

Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res (2001) 1.67

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59

Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis (2006) 1.29

miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops. Cell Res (2012) 1.17

Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res (2005) 1.13

Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11

Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell (2012) 1.09

First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clin Cancer Res (2012) 0.97

Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology (2010) 0.95

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck (2012) 0.88

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat (2013) 0.79